Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer

NCT06368141 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT06368141
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06368141 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer
Lead sponsor
Ruijin Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
May 1, 2024
Completion date
April 30, 2026
Enrollment
56 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer